Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 19.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 21.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | f the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 12.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 13.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 23.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 14.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Unternehmen & Branche
| Name | Ultragenyx Pharmaceutical Inc. |
|---|---|
| Ticker | RARE |
| CIK | 0001515673 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,42 Mrd. USD |
| Beta | 0,25 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 673,000,000 | -575,000,000 | -5.83 | 1,532,000,000 | -80,000,000 |
| 2025-09-30 | 10-Q | 159,933,000 | -180,413,000 | -1.81 | 1,190,445,000 | 9,159,000 |
| 2025-06-30 | 10-Q | 166,496,000 | -114,951,000 | -1.17 | 1,306,265,000 | 151,286,000 |
| 2025-03-31 | 10-Q | 139,292,000 | -151,080,000 | -1.57 | 1,311,927,000 | 144,246,000 |
| 2024-12-31 | 10-K | 560,000,000 | -569,000,000 | -6.29 | 1,503,000,000 | 255,000,000 |
| 2024-09-30 | 10-Q | 139,494,000 | -133,516,000 | -1.40 | 1,538,363,000 | 346,827,000 |
| 2024-06-30 | 10-Q | 147,026,000 | -131,598,000 | -1.52 | 1,618,437,000 | 432,418,000 |
| 2024-03-31 | 10-Q | 108,833,000 | -170,684,000 | -2.03 | 1,307,080,000 | 140,264,000 |
| 2023-12-31 | 10-K | 434,000,000 | -607,000,000 | -8.25 | 1,491,013,000 | 275,000,000 |
| 2023-09-30 | 10-Q | 98,052,000 | -159,649,000 | -2.23 | 1,238,140,000 | 31,714,000 |
| 2023-06-30 | 10-Q | 108,309,000 | -159,828,000 | -2.25 | 1,311,310,000 | 129,030,000 |
| 2023-03-31 | 10-Q | 100,496,000 | -163,972,000 | -2.33 | 1,383,404,000 | 220,481,000 |
| 2022-12-31 | 10-K | 363,329,000 | -707,421,000 | -10.12 | 1,545,444,000 | 352,000,000 |
| 2022-09-30 | 10-Q | 90,703,000 | -245,106,000 | -3.50 | 1,618,474,000 | 468,829,000 |
| 2022-06-30 | 10-Q | 89,343,000 | -158,162,000 | -2.26 | 1,320,627,000 | 678,073,000 |
| 2022-03-31 | 10-Q | 79,935,000 | -152,320,000 | -2.19 | 1,384,029,000 | 796,424,000 |
| 2021-12-31 | 10-K | 351,406,000 | -454,025,000 | -6.70 | 1,522,397,000 | 922,561,000 |
| 2021-09-30 | 10-Q | 81,647,000 | -72,998,000 | -1.08 | 1,484,801,000 | 933,674,000 |
| 2021-06-30 | 10-Q | 86,975,000 | -122,428,000 | -1.81 | 1,512,444,000 | 972,171,000 |
| 2021-03-31 | 10-Q | 99,395,000 | -136,141,000 | 1,597,763,000 | 1,054,582,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -4,683 | 20.97 | -98,202.51 | -64,9% | |
| 2026-03-10 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -3,508 | 22.67 | -79,526.36 | -52,6% | |
| 2026-03-06 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -6,018 | 21.40 | -128,785.20 | -85,2% | |
| 2026-03-03 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -1,635 | 22.40 | -36,624.00 | -24,2% | |
| 2026-03-02 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -8,135 | 22.80 | -185,478.00 | -122,7% | |
| 2026-03-02 | Harris Erik | Officer, EVP & Chief Commercial Officer | Open Market Sale | -10,539 | 22.80 | -240,289.20 | -158,9% | |
| 2026-03-02 | Pinion John Richard | Officer, See Remarks | Open Market Sale | -10,029 | 22.80 | -228,661.20 | -151,2% | |
| 2026-03-02 | KAKKIS EMIL D | Director, Officer, President & CEO | Open Market Sale | -54,404 | 22.80 | -1,240,411.20 | -820,3% | |
| 2026-03-02 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1,632 | 22.80 | -37,209.60 | -24,6% | |
| 2026-03-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,119 | 22.54 | -70,302.26 | -46,5% | |
| 2026-03-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -5,290 | 22.80 | -120,612.00 | -79,8% | |
| 2026-03-02 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -7,029 | 22.80 | -160,261.20 | -106,0% | |
| 2026-02-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,061 | 23.56 | -72,117.16 | -47,7% | |
| 2026-01-02 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,150 | 22.84 | -71,946.00 | -47,6% | |
| 2025-12-29 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -85 | 34.38 | -2,922.30 | -1,9% | |
| 2025-12-10 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -3,081 | 36.38 | -112,086.78 | -74,1% | |
| 2025-10-13 | Horn Howard | Officer, Chief Financial Officer | Open Market Sale | -7,942 | 31.51 | -250,252.42 | -165,5% | |
| 2025-09-18 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -64 | 29.17 | -1,866.88 | -1,2% | |
| 2025-09-12 | Parschauer Karah Herdman | Officer, EVP and Chief Legal Officer | Open Market Sale | -2,450 | 31.17 | -76,366.50 | -50,5% | |
| 2025-09-05 | Huizenga Theodore Alan | Officer, SVP, Chief Accounting Officer | Open Market Sale | -84 | 31.39 | -2,636.76 | -1,7% | |
| 2025-06-20 | Sanders Corazon (Corsee) D. | Director | Open Market Sale | -2,405 | 37.39 | -89,922.95 | -59,5% | |
| 2025-05-05 | Crombez Eric | Officer, EVP and Chief Medical Officer | Open Market Sale | -520 | 39.24 | -20,404.80 | -13,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.